PLXS Stock Price Plexus Corp Stock Quote U.S.: Nasdaq

10/09/2021

benefit from continued
plxp

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.16 per share. Plexus Corp reported Q4 EPS of $1.78, $0.51 better than the analyst estimate of $1.27. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.01… Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.

Plexus Corp’s second-quarter performance is likely to benefit from new manufacturing contract wins and growing secular market trends. Plexus’ second-quarter fiscal 2023 results benefit from continued momentum across all segments and regions. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity.

Opinion

Plexus uses resources or causes negative impacts mostly in categories “Scarce human capital”, “GHG emissions”, and “Societal stability & understanding among people”. The negative contribution in the “GHG emissions” impact category seems to be driven mostly by its “Military aircraft parts”, “Airplane components”, “Industrial robots”, and “Satellites” products. Plexus does not have a long track record of dividend growth. One share of PLXP stock can currently be purchased for approximately $0.01. By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion. Plexus’ fourth-quarter fiscal 2022 results benefit from a robust demand environment amid global macroeconomic uncertainty and geopolitical instability in Europe. Plexus doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Bank of New York Mellon reduces stake in The Brink’s Company – Best Stocks

Bank of New York Mellon reduces stake in The Brink’s Company.

Posted: Mon, 27 Mar 2023 07:00:00 GMT [source]

This is a decrease of -67% compared to the previous 30 days. 11 people have searched for PLRX on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days. MarketBeat has tracked 14 news articles for Pliant Therapeutics this week, compared to 3 articles on an average week.

Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

standard initial margin model‘ stock is owned by a number of institutional and retail investors. PLx Pharma’s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%).

Value investors frequently look for companies that have low price/book ratios. According to 5 analysts, the average rating for PLXS stock is “Strong Buy.” The 12-month stock price forecast is $105.4, which is an increase of 19.10% from the latest price. Plexus’ stock was trading at $102.93 at the beginning of the year. Since then, PLXS shares have decreased by 14.0% and is now trading at $88.50. Pliant Therapeutics’ stock was trading at $19.33 on January 1st, 2023.

Ciena (CIEN) Expands Portfolio With Tibit & Benu Acquisitions – Nasdaq

Ciena (CIEN) Expands Portfolio With Tibit & Benu Acquisitions.

Posted: Wed, 23 Nov 2022 08:00:00 GMT [source]

Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies. Plexus came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.16 per share.

Tech Stocks That Survived Nasdaq’s Bloodbath This Year

The technique has proven to be very useful for finding positive surprises. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with https://1investing.in/. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023.

This compares to earnings of $0.95 per share a year ago. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Merrill Lynch reinstated the electronics-manufacturing services company at “neutral.” The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023. The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Goldman Sachs sees restructuring lowering earnings by 2 cents per share per quarter. All values as of most recently reported quarter unless otherwise noted.

‘The Worst Is Over’ For Plexus

Claim your $200 account credit and free 30-day trial subscription today. This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies. Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value.

Plexus Corp.’s first-quarter performance is likely to have benefited from the improving demand environment and new program ramps. There may be delays, omissions, or inaccuracies in the Information. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

outstanding shares

Measures how much net income or profit is generated as a percentage of revenue.

Company Summary

Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a lower news sentiment than the 0.48 average news sentiment score of Computer and Technology companies.

segments and regions

Investors weren’t thrilled with the tech company’s fiscal second-quarter guidance. Live educational sessions using site features to explore today’s markets. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. Plexus shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. Plexus’ first-quarter fiscal 2023 results benefit from continued momentum across all segments and regions.

PLx Pharma (PLXP) Stock Forecast, Price & News

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

  • Plexus Corp’s second-quarter performance is likely to benefit from new manufacturing contract wins and growing secular market trends.
  • The company’s average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
  • Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
  • The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.

Pliant Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals.

There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” PLXS shares. 2 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for PLx Pharma in the last year. The consensus among Wall Street research analysts is that investors should “hold” PLXP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLXP, but not buy additional shares or sell existing shares. Plexus Corp share price live 88.50, this page displays NASDAQ PLXS stock exchange data.

11 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Pliant Therapeutics in the last twelve months. The consensus among Wall Street equities research analysts is that investors should “buy” PLRX shares. 5 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Plexus in the last year.

Pliant Therapeutics does not have a long track record of dividend growth. Right-click on the chart to open the Interactive Chart menu. Barchart is committed to ensuring digital accessibility for individuals with disabilities. We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests.

Compartilhar

Acesse agora meu e-book exclusivo

Aprenda a escolher o arquiteto certo nesse material gratuito.